INFORMED CONSENT FOR A PRESCRIPTION DRUG - IMPACT OF DISCLOSED INFORMATION ON PATIENT UNDERSTANDING AND MEDICAL OUTCOMES

被引：30

作者：

QUAID, KA

FADEN, RR

VINING, EP

FREEMAN, JM

机构：

[1] JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205

[2] JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205

[3] JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT NEUROL,BALTIMORE,MD 21205

[4] JOHNS HOPKINS UNIV,SCH MED,DIV HLTH POLICY,BALTIMORE,MD 21205

来源：

PATIENT EDUCATION AND COUNSELING | 1990年 / 15卷 / 03期

关键词：

Informed consent; Medical ethics;

D O I：

10.1016/0738-3991(90)90100-Y

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Based on the two legal standards of informed consent currently in use, the Medical Practice Standard and the Reasonable Person Standard, two disclosures containing information about the risks and benefits of the anticonvulsant, Carbamazepine, were empirically derived. One of these two disclosures was randomly given to a sample of 39 seizure patients and the parents of pediatric seizure patients prescribed this drug. Subjects were interviewed either immediately after disclosure and at followup, or at followup only. The results provide no evidence for the hypothesized negative effects - anxiety, treatment refusal, reduced compliance and increased side effects - of providing patients with extensive disclosures about prescription drugs. © 1990.

引用

页码：249 / 259

页数：11

共 29 条

[1]

American Medical Association, 1983, AMA DRUG EV

[2] PATIENT EDUCATION AND INTRAUTERINE CONTRACEPTION - STUDY OF 2 PACKAGE INSERTS [J].